Elan (ELN) implied volatility Elevated into Phase 3 for Alzheimer's
Elan (NYSE: ELN) : ELN, a neuroscience-based biotechnology company, is recently at $18.40 in pre-open trading, above its close of $16.60. SBSH say's "ELN & WYE announced overnight that the companies have decided to move bapineuzumab, their most advanced program for the treatment of Alzheimer's disease, into Phase 3 clinical development." ELN June option implied volatility of 57 is near its 26-week average, above its 3-month average of 52 according to Track Data. Paul Foster
You May Also Be Interested In
- Facebook (FB) Up on S&P 500 Addition Speculation
- Auxilium Pharma (AUXL) Slumps; Court Grants Summary Judgment in Testin Gel Suit
- 3D Systems (DDD) Trades Higher Following Launch of Two New 3-D Printers (VJET) (SSYS)
Create E-mail Alert Related CategoriesOptions
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!